Business Wire

CA-NETAPP

20.6.2024 17:01:27 CEST | Business Wire | Press release

Share
Spot by NetApp Achieves FinOps Foundation's Certified Platform Certification

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Spot by NetApp has achieved the FinOps Certified Platform certification from the FinOps Foundation, validating the platform's ability to provide the depth and breadth of capabilities organizations need to practice sound cloud financial management. Also, Spot by NetApp has expanded its certified platform with the general availability of its Cost Intelligence and Billing Engine solutions.

As organizations move increasing amounts of their workloads to the cloud, especially to fuel the development of AI applications, balancing the competing needs of infrastructure and financial efficiency becomes more difficult. Overprovisioning cloud resources results in wasted expenses, but under-provisioning can slow business operations and stifle innovation. The traditional approach of standalone FinOps tools, with their focus on cost cutting, fall short of meeting these evolved requirements to deliver cost-effective yet high-performance cloud infrastructure.

Spot by NetApp closes this technology gap by delivering a holistic, integrated portfolio of FinOps solutions that supports an organization’s intelligent data infrastructure. With its breadth of capabilities, organizations can unify cloud cost and infrastructure optimization, deliver analytics to maximize the efficiency and impact of every dollar spent in the cloud, and drive digital business growth. Becoming a FinOps Certified Platform helps Spot by NetApp enable its customers to successfully adopt cloud best practices aligned with the FinOps standards.

“According to the FinOps Framework, implementing a productive FinOps strategy requires effective collaboration between teams. Effective collaboration requires full access to both financial and cloud operations data,” said Mike Fuller, CTO of the FinOps Foundation. “A thoughtful and comprehensive approach to FinOps helps organizations maximize the business value of the cloud so they can more easily achieve their business goals. We recognize Spot by NetApp as a FinOps Certified Platform due to its ability to deliver software that helps organizations successfully adopt FinOps practices.”

To support this comprehensive approach to FinOps, Spot by NetApp has integrated the cloud cost management capabilities of Cloudcheckr into its portfolio with the introduction of two new product modules:

  • Cost Intelligence: This product delivers panoramic visibility with actionable insights on cloud costs, resources, and usage across multi-cloud environments through interactive dashboards and drill down reports. To support the cost optimization process, Cost Intelligence provides best practice checks that immediately flag problems and help users optimize spend, effectively utilize resources, reduce waste, and address misconfigurations.
  • Billing Engine: This product provides comprehensive billing reporting with intelligent cost allocation capabilities including chargeback and showback. With this product, businesses can better track and manage cloud spend across different groups to drive accountability.

FinOps teams will benefit from a single source of truth for financial and cloud operations data. The release of Cost Intelligence and Billing Engine improves the effectiveness of all solutions in the Spot by NetApp portfolio. For example, organizations will be able to use Spot Ocean and Elastigroup’s machine learning and AI analytics together with Cost Intelligence’s advanced cost analysis to deliver the most accurate optimization recommendations. Teams can further simplify their FinOps practices by automatically applying those recommendations to their infrastructure.

“The expansion of our integrated FinOps offering and becoming a FinOps Certified Platform is a true validation of Spot by NetApp's vision and approach to leveraging data and technology to help customers get the most from their cloud investments,” said Haiyan Song, Executive Vice President of Cloud Operations at NetApp. “Our comprehensive and integrated portfolio spans financial management and continuous cloud infrastructure optimization. We continue to innovate and evolve our cutting-edge AI powered solutions, harnessing the intelligence from the vast workloads and infrastructure under management by Spot by NetApp to provide critical insights in FinOps management and enable autoscaling and continuous optimization. Expanding our FinOps offerings with Cost Intelligence and Billing Engine is another step forward in our ongoing mission to support our customers and unlock more value from the cloud.”

To learn more about the Spot by NetApp solution for FinOps, visit the Spot by NetApp booth #G3 at the FinOps X conference running from June 19-22 at The Marriott Marquis, San Diego

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620996726/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye